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Abstract
We set out to study the key effectors of resistance and sensitivity to ErbB2 tyrosine kinase inhibitors, such as lapatinib in
ErbB2-positive breast and lung cancers. A cell-based in vitro site-directed mutagenesis lapatinib resistance model identified
several mutations, including the gatekeeper ErbB2 mutation ErbB2-T798I, as mediating resistance. ErbB2-T798I engineered
cell models indeed show resistance to lapatinib but remain sensitive to the irreversible EGFR/ErbB2 inhibitor, PD168393,
suggestive of potential alternative treatment strategies to overcome resistance. Gene expression profiling studies identified
a select group of downstream targets regulated by ErbB2 signaling and define PHLDA1 as an immediately downregulated
gene upon oncogenic ErbB2 signaling inhibition. We find significant down-regulation of PHLDA1 in primary breast cancer
and PHLDA1 is statistically significantly less expressed in ErbB2 negative compared with ErbB2 positive tumors consistent
with its regulation by ErbB2. Lastly, PHLDA1 overexpression blocks AKT signaling, inhibits cell growth and enhances
lapatinib sensitivity further supporting an important negative growth regulator function. Our findings suggest that PHLDA1
might have key inhibitory functions in ErbB2 driven lung and breast cancer cells and a better understanding of its functions
might point at novel therapeutic options. In summary, our studies define novel ways of modulating sensitivity and
resistance to ErbB2 inhibition in ErbB2-dependent cancers.
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Introduction
ErbB2 is a cell membrane surface-bound receptor tyrosine
kinase and is involved in the signal transduction pathways leading
to cell growth and proliferation. This gene is amplified in 10–20%
of breast cancers, and amplification results in protein overexpres-
sion, which denotes an aggressive phenotype [1–4]. Overexpres-
sion, amplification and occasionally activating mutations of ErbB2
also occur in other cancers, including non-small cell lung cancer
[5,6]. The humanized antibody trastuzumab (Herceptin) against
the overexpressed ErbB2 is proven to be effective in treating breast
and gastric cancers with ErbB2 amplification [7]. Further, somatic
mutations in the kinase domain of ErbB2 were discovered in
various solid cancers including lung and breast carcinomas [8–12].
More recently, dual EGFR/ErbB2 tyrosine kinase inhibitors have
also shown promise in clinical studies. A dual, reversible EGFR/
ErbB2 inhibitor, lapatinib (Tykerb) in particular has demonstrated
significant activity in ErbB2-positive breast cancers and now is
approved to be used in this indication [13]. http://en.wikipedia.
org/wiki/HER2/neu - cite_note-3Inhibition of ErbB2 tyrosine
autophosphorylation by lapatinib abrogates downstream Ras-Raf-
ERK1/2 and PI3K-AKT growth/survival signaling in ErbB2
overexpressing breast cancer cell lines and in patients with ErbB2-
overexpressing breast cancers [14].
The uniform development of acquired resistance to lapatinib
unfortunately limits its clinical efficacy. In analogous settings,
secondary mutations, such as KIT exon 17 mutations in imatinib-
resistant GIST and EGFR T790M in EGFR-mutated lung
cancers are common mechanisms of resistance [8,15]. There is
no in vivo data currently available on potential mechanisms of
resistance to lapatinib. In an in vitro model system, the secondary
mutation, ErbB2 T798I imparts the strongest lapatinib resistance
effect in Ba/F3 cells and is analogous to the epidermal growth
factor receptor T790M [16–18]. A recent study suggests that in in
vitro model systems the development of co-dependence on ER-
signaling pathways might be another potential mechanism to
lapatinib resistance [19]. There is also data to suggest the
involvement of AXL activation in lapatinib-resistance in ErbB2
positive breast cancer [20]. Clearly, other mechanisms exist as
well. Given the difficulties of obtaining primary patient specimens,
it is important to construct experimental cellular systems to screen
for relevant resistance mechanism that then permit testing of
alternative inhibitors to overcome resistance. It is clearcut that the
AKT/PI3K and ERK/MAPK pathways are key immediate
downstream effectors of ErbB2 oncogenic signaling. However,
their targeting has serious shortcomings in terms of toxicity and a
narrow therapeutic index given their important physiological roles.
Therefore, a better understanding of the entire array of
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downstream changes should allow the identification of novel
actionable targets and the development of more effective and
durable strategies for the treatment of ErbB2-positive cancers.
In our study, we set out to the dual goal to advance our
understanding in both of these pivotal areas of oncogenic ErbB2
signaling- acquired resistance and downstream effector and
modulator pathways. First, we established sensitivity to lapatinib
treatment of ErbB2-positive lung and breast cancer cell lines,
identified an array of putative acquired resistance mutations and
demonstrated that mutations of ErbB2-T798 lead to resistance
that can be overcome by the irreversible ErbB2 inhibitor,
PD168393. Next, we completed a gene expression profiling study
identifying a key group of early ErbB2 target genes and identify
PHLDA1 as a novel downstream target of ErbB2 signaling with a
functional role in negative feedback mechanisms to fine-tune the
output of ErbB2 signaling and thereby significantly enhancing the
sensitivity of ErbB2-positive breast cancer cells to lapatinib. Our
studies provide several new avenues to extend the benefits of
ErbB2 inhibition in the management of ErbB2-dependent cancers.
Materials and Methods
Patient Material
The breast cancer tissue and the normal breast tissue
surrounding the tumor were obtained from same patient. The
formalin-fixed tissues were used for immunohistochemistry study.
The project was approved by the Ethics Committee of New York
Presbyterian Hospital of Columbia University, and the patients
gave written consent in accordance with the Declaration of
Helsinki.
Reagents
EGF was purchased from Sigma-Aldrich (St. Louis, MO),
PD168393 and CL387,785 were purchased from Calbiochem
(Billerica, MA), lapatinib was purchased from SELLECK Chem-
icals (Houston, TX). Drugs were dissolved in DMSO to give a
10 mmol/L stock solution and the final DMSO concentration in
all experiments was ,0.1%.
Cell Culture
Calu3, HCC827, H1975, HCC202, HCC1569, HCC1937 and
T47D cells were maintained in RPMI 1640 supplemented with
10% FBS, SkBr3 cells were maintained in McCoy’s medium
supplemented with 10% FBS. MDA-MB-468 and MDA-MB-436
cells were maintained in Leibovitz’s L-15 medium supplemented
with 10% FBS, MCF-7 cells were maintained in DMEM medium
supplemented with 10% FBS. All cells were grown at 37uC in a
humidified atmosphere with 5% CO2 and were in the logarithmic
growth phase at the initiation of all experiments. MCF-7, MDA-
MB-468 and MDA-MB-436 cells are provided here courtesy of
Dr. Matthew Maurer (Columbia University). All cell lines were
originally purchased from ATCC (Manassas, VA).
ErbB2 mutagenesis, library generation, and drug
resistance screen
The plasmid construct pcDNA3.1(-)-ErbB2-HA was generated
as previously described [8]. We introduced a new enzyme site-
AgeI at position 1457 in the ErbB2 cDNA. Then we shuffled the
entire transmembrane and tyrosine kinase binding domain of
ErbB2 by AgeI-AfeI digestion (AfeI site- position 3191). Using the
mutated pcDNA3.1(-)-ErbB2-HA plasmid, we performed random
mutagenesis using primers spanning the 1457-3191 region in the
presence of 50 mmol/L MnCl2. Subcloning into p-GEM-T Easy
vector and sequencing of individual colonies showed that
essentially all of the PCR products contained mutations, with
50% of the products containing a 1-bp change. The pool of
amplified DNA fragments was digested with AgeI and AfeI and
religated into the backbone pcDNA3.1(-)-ErbB2-HA vector.
Parental SkBr3 cells were transfected with the mutagenized
libraries. Cell clones were selected by fresh medium containing
500 mg/mL G418 and 1 mmol/L lapatinib after 24-hour trans-
fection. One month later, cell colonies were isolated and further
amplified in the presence of both G418 and lapatinib and then the
tyrosine kinase domain of ErbB2 was resequenced. Sequence
alignment and analysis was done with DNASTAR and Mutation
SURVEYOR software (SoftGenetics, State College, PA).
Generation of the ErbB2 T798I plasmid construct
The ErbB2 T798I expression vector was generated by site-
directed mutagenesis (QuickChange mutagenesis kit, Stratagene,
Santa Clara, CA) of the pcDNA3.1(-)-ErbB2-HA plasmid
construct. The primers used for site-directed mutagenesis were
T798I, 59-CACGGTGCAGCTGGTGATACAGCTTATGCC-
CTATG-39 (sense) and 59-CATAGGGCATAAGCTGTATCAC-
CAGCTGCACCGTG-39 (antisense). The proper sequence of the
generated construct was confirmed by resequencing. We also
constructed an ErbB2 wild type expression construct as the control
for transfection assays. Transient transfection studies were done
using Cos-7 cells with these reconstructed plasmids. Western blot
analysis was used to confirm the success of transfection with the
use of an anti-hemagglutinin tag antibody. G418 (500 mg/mL) was
used to select stably transfected cells and isolated colonies were
picked using cloning rings and continued to be cultured in the
presence of G418. Expression of the ErbB2 T798I mutant protein
was confirmed by the detection of the expression of the
hemagglutinin tag as above.
Cell Growth Inhibition Analysis
Cells were plated in each well of 96-well plates in cell medium
containing 10% FBS. 24 hours after plating, cells were treated
with specified concentrations of inhibitors. The concentration of
DMSO in the medium was adjusted to 0.1%. After 72 hours of
incubation, viable cell numbers were measured by using 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium, inner salt (MTS; absorption of formazan at
490 nm; CellTiter96, Promega, Madison, WI) according to the
manufacturer’s protocol. Each assay consisted of three replicate
wells of the same drug concentration. The IC50 was determined
from the dose-response curves.
Immunoblotting
To assess ErbB2 signaling activation, cells were starved for
12 hours and then incubated with lapatinib or PD168393 for
3 hours followed by EGF (100 ng/ml) or heregulin (20 ng/ml)
stimulation for 15 minutes. Whole cell lysates were separated on
8% SDS-polyacrylamide gels, transferred to nitrocellulose, and
protein expression was detected by the use of Western Lightning
Chemiluminescence Reagent (Perkin-Elmer Life Science, Well-
esley, MA). Phospho-Akt (Ser473), phospho-ERK 1/2 (T202/
Y204), total-Akt, total-ERK and GAPDH antibodies were
purchased from Cell Signaling Technology (Beverly, MA).
Antibodies to ErbB2 (C-18), PHLDA1 [21-23] and hemagglutinin
tag (F-7) were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibody directed against phospho-ErbB2 (Y1248) was
purchased from R&D systems (Minneapolis, MN). Secondary anti-
mouse and anti-rabbit antibodies were purchased from Santa Cruz
Biotechnology. Experiments were repeated three times.
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Annexin/propidium iodide and BrdU assays
For both assays, samples were analyzed on a fluorescence-
activated cell scan cytometer EPICS XL MCL (Beckman Coulter,
Miami, FL). Annexin/propidium iodide (PI) apoptosis assay was
performed according to the manufacturer’s instructions (Annexin
V-FLUOS staining kit, Roche Applied Science, Indianapolis, IN).
Cells were seeded at 16106 cells/well on 10 cm plates; 24 hours
after plating media was refreshed to specified concentrations of
inhibitors, then incubated for an additional 72 hours. Cells were
then trypsinized, washed with PBS, resuspended in Annexin/
Propidium iodide staining buffer (Roche Applied Science), and
then analyzed by flow cytometry. Data were analyzed with FlowJo
software (Tree Star, Ashland, OR). Bromo-deoxyuridine (BrdU)
cell proliferation assay was performed according to the manufac-
turer’s instructions (FITC BrdU Flow Kit, BD Pharmingen, San
Diego, CA). Briefly, Calu3 cells were treated with lapatinib at
different concentrations (final concentration: 0, 0.1, 1, 3, and
10 mmol/L) for 3 days, then pulse labeled for 60 min with 10 mM
BrdU, collected by trypsinization and permeabilized with BD
cytoperm buffer, stained with fluorescent anti-BrdU antibody,
counterstained with 7-amino-actinomycin D for total DNA
content and analyzed by flow cytometry. Experiments were
repeated at least three times.
Oligonucleotide Array Analysis
Calu3 and SkBr3 cells were grown to 60% confluence in culture
medium and then were treated with lapatinib (1 mm), or DMSO
(0.01%) as a control for 6 hours. Total cellular RNA was isolated
using the RNAeasy mini kit (Qiagen, Germantown, MD). RNA
quality was assessed using Experion Automated Electrophoresis
Station (Bio-Rad) and quantified by fiberoptic spectrophotometry
using the Nanodrop ND-1000 (Nanodrop Inc., Wilmington, DE,
USA). cDNA was synthesized, labeled and hybridized to
Affymetrix HG-U133A microarrays and scanned. The expression
value for each gene was calculated using Affymetrix GeneChip
software and the Robust Multichip Average (RMA) method for
signal extraction.
Preprocessing, Filtering, and Statistical analysis
The microarray data were analyzed and the false discovery rate
was calculated using SAM (Stanford University, CA). Array
normalization and computation of expression values of the chip
were performed using DNA-Chip Analyzer (dchip). For annota-
tion of the resulting genes, the gene ontology browser NetAffyme-
trix (http://ww.affymetrix.com) was used. The differentially
expressed genes with $2 or #0.5 fold change, q-value #1%
were analyzed using t test and clustered with the software package
cluster 3.0 [24].
Quantitative PCR Assay
Total RNA from triplicate samples was isolated by using
RNAeasy mini kit (Qiagen). cDNA was synthesized with M-MLV
reverse transcriptase (SuperScipt III reverse transcriptase, Invitro-
gen, Grand Island, NY) with the use of oligo(dT) primers from
Invitrogen. All samples were analyzed by Roche LightCycler using
the Syber green probes. Primer sequences are shown in Table S1.
Levels of GAPDH expression were used as internal references to
normalize input cDNA. Ratios of level of each gene to GAPDH
were then calculated.
Immunohistochemistry
Formalin-fixed primary breast tumor tissue sections were
deparaffinized and rehydrated and incubated with 0.6% hydrogen
peroxide in methanol. Target retrieval solution, pH 9.0 (Dako,
Carpinteria, CA) was used for antigen retrieval. The slides were
incubated with primary antibodies for overnight at 4uC followed
by staining using the R.T.U Vectastain Universal Quick Kit
(Vector Laboratories, Burlingame, CA) with hematoxylin nuclear
counterstaining. Finally, slides were dehydrated sequentially in
ethanol, cleared with xylenes. The anti-PHLDA1 antibody was
used in 1:50 dilution (Santa Cruz Biotechnology). The intensity of
the staining of PHLDA1 was scored by a board certified breast
cancer pathologist as 0 (no expression), 1+ (weak expression), 2+
(moderate expression) and 3+ (strong expression) and the
percentage (0–1.0) of positively stained tumor cells was also
evaluated to generate a composite H-score (intensity score X
percent positive, range of possible values 0–3.0). Silver in situ
hybridization (SISH) was used to determine ErbB2 status in
human breast cancer samples [25]. The ratio of ErbB2/
chromosome 17 was calculated by dividing the total score for
ErbB2 by the total score for chromosome 17. A ratio of ,1.8
indicated that ErbB2 gene was not amplified, whereas a ratio of
.2.2 indicated amplification of the gene. For cases with a ratio
between 1.8 and 2.2, signals from 20 more tumor nuclei were
counted in each slide and a new ratio was calculated.
Plasmid constructs and cellular transfection
Full length cDNA sequence of human PHLDA1 was amplified
from genomic DNA of HCC827 cells. PHLDA1 was then
modified with an HA-tag at the C-terminus by overlapping PCR
to distinguish plasmid derived from native protein and was
subcloned into the pcDNA3.1(-) backbone vector. The accuracy of
the construct was confirmed by direct DNA sequencing. SkBr3
cells were transiently transfected with empty pcDNA3.1(-)
(pcDNA3.1(-)-EV) or PHLDA1 (pcDNA3.1(-)-PHLDA1) expres-
sion vectors using Fugene 6 (Roche Applied Science). Stably
transfected subclones were selected with G418 at a concentration
of 500 mg/ml starting 48 h posttransfection.
Anchorage independent growth assay and migration
assay
For anchorage independent growth assay, pcDNA3.1(-)-EV and
pcDNA3.1(-)-PHLDA1 stable transfected cells were trypsinized,
counted twice using a hemocytometer, and plated at 5000 cells/ml
in top plugs consisting of 0.4% SeaPlaque agarose (FMC
Bioproducts, Rockland, ME) in McCoy’s 5A medium. After 25
days, the colonies were photographed and counted. The
experiment was repeated three times with triplicates each. Average
numbers of colonies from each experiment were plotted. For
migration assays, confluent monolayers of pcDNA3.1(-)-EV and
pcDNA3.1(-)-PHLDA1 stable transfected cells were scratched with
a sterile 10 ml pipette tip. The plates were then washed and
incubated at 37uC in 10%FBS/McCoy’s 5A medium for
48 hours.
Clonogenic survival assay
Two thousand pcDNA3.1(-)-EV and pcDNA3.1(-)-PHLDA1
SkBr3 cells were plated onto 6 cm plates and were allowed to
recover for 24 hours. Cells were then treated with 0.1 mM or
0.5 mM lapatinib and were allowed to grow for 10 days. Next, the
plates were stained with Methylene Blue for 4 hours and the
number of colonies with more than 50 cells in each plate were
determined. A set of untreated plates were included as controls to
determine the plating efficiency for individual cell lines. The
effective number of cells/plate was determined on the basis of the
plating efficiency of each cell line and the number of cells plated
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per plate. These numbers were then used to calculate the
percentage survival. Also, each treatment was performed in
triplicates in order to determine the SD for each data point.
Statistical analysis
Statistical analyses were performed using chi-squared test or
two-sample t-tests as appropriate, with P-value of ,0.05
considered statistically significant. Data are expressed as mean 6
SD. The data are representative of three separate experiments.
Figure 1. Antitumor effects of lapatinib and PD168393 in the ErbB2 positive lung cancer cell line, Calu3 and the ErbB2 positive
breast cancer cell line, SkBr3 after 72 hour treatment. A. Cellular proliferation of Calu3 and SkBr3 cells treated with different concentrations of
lapatinib and PD168393 as determined by the MTS assay. B. Lapatinib and PD168393 induce cellular apoptosis in Calu3 and SkBr3 cells.
Representative Annexin V/propidium iodide flow cytometry; the numbers represent percentage of cells in the appropriate quadrant. C. Quantification
of apoptosis. D. Lapatinib induces cell cycle arrest in Calu3 cells as detected by BrdU and 7-ADD assay. R1-G1 phase; R2-G2 phase; R3-S phase; R4-G0
phase. E. Dose response of lapatinib and PD168393 on phosphorylation of ErbB2, AKT and ERK in Calu3 and SkBr3 cells in response to EGF treatment.
p-ErbB2: phosphorylated ErbB2; t-ErbB2: total-ErbB2; p-AKT: phosphorylated AKT; t-AKT: total AKT; p-ERK: phosphorylated ERK; t-ERK: total ERK.
doi:10.1371/journal.pone.0106349.g001
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Results
Lapatinib and PD168393 induce growth inhibition and
apoptosis in ErbB2-positive Calu3 and SkBr3 cells
We first conducted MTS cell growth assays to examine whether
inhibition of ErbB2 by lapatinib, a reversible dual EGFR/ErbB2
tyrosine kinase inhibitor, or PD168393, which irreversibly inhibits
ErbB2, can lead to growth inhibition of ErbB2-positive cancer
cells, such as ErbB2-positive Calu3 lung cancer and SkBr-3 breast
cancer cell lines. We found that both lapatinib and PD168393
significantly inhibited the growth of Calu3 and SkBr3 cells
(Fig. 1A). Further investigation using Annexin V staining showed
that both lapatinib and PD168393 induced prominent apoptosis in
both Calu3 and SkBr3 cells (Fig. 1B and 1C). BrdU incorporation
analysis was performed to show the reduced proliferation of these
two cell lines by lapatinib treatment. The lapatinib treated Calu3
cells showed a significantly higher G1 population consistent with
G1 arrest compared with control cells (Fig. 1D) and this was
further confirmed in SkBr3 cells (Figure S1). These results suggest
that lapatinib induces cell cycle arrest in the G1 phase and
subsequent apoptosis in Calu3 and SkBr3 cells. In order to
determine the effect on downstream signaling pathways, the
phosphorylation levels of the MAP kinase and AKT pathways
were assessed in these two ErbB2-positive cell models, and robust
Figure 2. The irreversible inhibitor PD168393 overcomes lapatinib resistance caused by the ErbB2 T798I mutation. A. Dose response
of lapatinib and PD168393 on phophorylation of ErbB2 in Cos7 cells after 24 hours of transient transfection with ErbB2-wt and ErbB2-T798I vectors.
Total ErbB2, HA and GAPDH expression level as control. B. Dose response of lapatinib and PD168393 on phosphorylation of ErbB2, AKT and ERK in
ErbB2-wt and ErbB2-T798I stable Calu3 cell clones. Total ErbB2, total AKT, total ERK, HA and GAPDH expression level as control. C. Dose-dependent
growth inhibition induced by the treatment of lapatinib and PD168393 for 72 hours in ErbB2-wt and ErbB2-T798I stable Calu3 cell clones as detected
by the MTS assay. D. Lapatinib and PD168393 induce cellular apoptosis in ErbB2-wt and ErbB2-T798I stable Calu3 cell clones after 72 hour treatment.
E. Quantification of apoptosis.
doi:10.1371/journal.pone.0106349.g002
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blockade of both signaling pathways was found (Fig. 1E, Figure
S2). This finding was correlated with the results of the growth
inhibition assays done, suggesting that the growth inhibition
caused by lapatinib and PD168393 may be regulated through
effective blockade of the MAP kinase and AKT pathways.
Characterization of resistance mutant ErbB2-T798I
Next, we pursued a random mutagenesis strategy in order to
assess secondary mutations of ErbB2 that can lead to functional
resistance to lapatinib. First, the entire transmembrane and
tyrosine kinase domain of ErbB2 (positions 1457–3191) was
randomly mutagenized. Then, the mutagenized ErbB2 was
reshuffled into a pcDNA3.1(-)-ErbB2-HA backbone and trans-
fected into SkBr-3 cells. We generated drug-resistant SkBr-3 cell
clones in the presence of both 500 mg/mL G418 and 1 mmol/L
lapatinib and identified 9 distinct amino acid substitutions
affecting 5 residues from isolated clonal derivatives. Substitutions
at five positions were identified: P944L (3 cases), T798I (2 cases),
T798M (1 case), C576S (1 case), R487P (1 case), and E542G (1
case). The critical gatekeeper threonine residue in the case of
ErbB2 is T798- which corresponds to T790 of EGFR as well as
T315 of the ABL kinase. Based on the nucleotide sequence of
ErbB2, it is significantly more likely that a mutation would alter
the sequence to T798I (requires one base pair change) versus
T798M (requires two base pair changes). Therefore, T798I was
chosen for further studies.
T798I was regenerated by site-directed mutagenesis and used
for transient transfection studies in Cos-7 cells. In pcDNA3.1(-)-
ErbB2-wt Cos7 cells, 1 mmol/L lapatinib significantly inhibited
phosphorylation of ErbB2. In contrast, in pcDNA3.1(-)-ErbB2-
T798I transfectants, persistent ErbB2 phosphorylation was noted
in the presence of lapatinib at concentrations ranging from 0.1 to
10 mmol/L, confirming the shift in drug sensitivity corresponding
to the findings of the MTS assays (Fig. 2A). To confirm this
observation, we also generated a stably transfected Calu3 cell
clone with the pcDNA3.1(-)-ErbB2-T798I-HA plasmid construct
Figure 3. PHLDA1 is regulated by ErbB2 inhibition at the mRNA level at 6 hours. Quantitative PCR analysis of gene regulation by lapatinib
treatment for 6 hours in SkBr3 and Calu3 cells. Fold induction relative to 0 hour control was plotted after normalization by GAPDH. D: p,0.05;6: p,
0.01; {: p,0.005; *: p,0.001.
doi:10.1371/journal.pone.0106349.g003
Table 1. List of the overlapping regulated genes between ErbB2 blockade by lapatinib in SkBr3 cells and EGFR blockade by CL-
387,785 in H1975 cells.
Gene ID ErbB2 blockade Fold Change EGFR blockade Fold Change Gene Name
221986_s_at 4.95483 2.78 KLHL24
212675_s_at 2.903494 2.01 KIAA0582 protein
202769_at 2.013582 3.12 CCNG2
201631_s_at 0.304776 0.45 IER3
209803_s_at 0.125931 0.47 PHLDA2
209457_at 0.460962 0.45 DUSP5
208892_s_at 0.126178 0.24 DUSP6
201464_x_at 0.491798 0.43 JUN
204014_at 0.38073 0.27 DUSP4
203499_at 0.125657 0.47 EPHA2
204420_at 0.112585 0.33 FOSL1
208712_at 0.150877 0.42 CCND1
204363_at 0.311877 0.34 F3
doi:10.1371/journal.pone.0106349.t001
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and found very consistent result (Fig. 2B). We assessed the level of
resistance that pcDNA3.1(-)-ErbB2-T798I conferred to lapatinib
by generating dose-response curves by MTS assays on
pcDNA3.1(-)-ErbB2-T798I stable transfectants. Cells were cul-
tured in the presence of increasing concentrations of lapatinib
ranging from 0 to 10 mmol/L. pcDNA3.1(-)-ErbB2-wt Calu3 cells
were potently inhibited by lapatinib (IC50, 2.3 mmol/L). Calu3
cells expressing pcDNA3.1(-)-ErbB2-T798I were less sensitive to
lapatinib with an IC50, 6.5 mmol/L (Fig. 2C).
We further analyzed the functional consequences of T798I by
assessing cellular apoptosis induced by lapatinib as defined by
Annexin/propidium iodide apoptosis assays. Treatment of
pcDNA3.1(-)-ErbB2-wt Calu3 cells with 1 mmol/L of lapatinib
resulted in a prominent increase in the percentage of apoptotic
cells, whereas the same concentrations had induced significantly
less apoptosis in pcDNA3.1(-)-ErbB2-T798I stable transfectants
(Fig. 2D and 2E). These results were consistent with transient
transfection studies pursued in SkBr3 cells (Figure S3, S4 and S5).
An alternative ErbB2 inhibitor PD168393 can overcome
resistance
Next, we tested the T798I Calu3 clones against the irreversible
ErbB2/EGFR inhibitor PD168393. We carried out standard
MTS assays following 72 hours of drug treatment using a range of
concentrations from 0 to 10 mmol/L. Our data showed that
PD168393 could overcome T798I induced resistance against
lapatinib (Fig. 2C). This inhibitor was as effective against
pcDNA3.1(-)-ErbB2-T798I as against pcDNA3.1(-)-ErbB2-wt
transfectants. In signaling studies, we found that PD168393
completely inhibits AKT and ERK phosphorylation at concen-
trations as low as 0.03 mmol/L so that in order to better show the
downstream signaling change, we used a range of concentrations
from 0 to 0.1 mmol/L. Signaling studies showed that treatment
with PD168393 can potently inhibit downstream signaling
correlates such as phospho-AKT and ERK (Fig. 2B). ErbB2
phosphorylation level in cells with mutant ErbB2 was altered but
to a lesser degree by PD168393 inhibition suggestive of partial
inhibition (Fig. 2B). Annexin/propidium iodide studies further
showed the induction of apoptosis by this compound in both
pcDNA3.1(-)-ErbB2-wt and pcDNA3.1(-)-ErbB2-T798I Calu3 cell
clones (Fig. 2D and 2E). These results suggest that T798I might be
an important resistance mechanism in lapatinib-treated tumors
but also suggest potential efficacy of irreversible ErbB2 inhibitors.
Gene expression profiling of lapatinib-treated cells
Next, we set out to study a comprehensive array of downstream
changes as a result of effective ErbB2 inhibition. Previously, in
similar studies we have shown that as early as at 6 hours of
signaling inhibition, the irreversible EGFR inhibitor, CL-387,785
could induce a significant change of transcription in a small and
representative group of key downstream effectors of oncogenic
EGFR signaling, including important pathway components such
as Cyclin D1, DUSPs etc in EGFR mutant lung cancers [1,26,27].
In an analogous fashion, we set out to identify the early effectors of
ErbB2 induced gene expression changes in ErbB2-positive cells.
To identify the key genes differentially expressed in SkBr3 cells
treated with lapatinib (1 mmol/L) for 6 hours, a gene expression
profiling study was done in triplicates on total cellular RNA using
Affymetrix HG-U133A chips. The raw expression data were
preprocessed, rescaled, filtered, and analyzed as described in
Materials and Methods. The genes altered by lapatinib treatment
are shown in Table S2. This analysis showed that 110 marker
genes were down-regulated and 73 genes were up-regulated with
the strict criteria set of an at least 2 fold change and Delta value .
5 when lapatinib-treated samples were compared with vehicle-
treated cells (the Delta value is a tuning parameter that can
dynamically change thresholds for significance).
A comparison of this gene list with our previous data identifying
gene changes upon EGFR inhibition in EGFR-dependent lung
cancer cells [27,28] showed a remarkable overlap between the
significantly modulated genes in the two independent experiments
(Table 1). More than half of the genes identified in our previous
study of gene regulation by EGFR blockade were significantly
modulated upon ErbB2 inhibition in ErbB2-positive cancer cells as
well suggesting highly shared oncogenic pathways. Six of the top
ErbB2/EGFR-regulated genes, DUSP6, DUSP4, PHLDA1,
PHLDA2, CCNG2 and DRE1 were selected and confirmed to
be strongly regulated by quantitative reverse transcription-PCR
analysis on RNA obtained from lapatinib-treated cells (Fig. 3).
PHLDA1 is down-regulated by EGFR/ErbB2 inhibition
We then decided to focus on the novel downstream target gene,
PHLDA1 as a protein that previously was not identified to
participate in ErbB2/EGFR driven pathways. This gene belongs
to the group of pleckstrin-homology domain proteins and is
speculated to function through interfering with the function of PI3-
kinase thereby inhibiting AKT activation based on work on
another family member, PHLDA3 [29]. Western blotting analysis
indeed showed that PHLDA1 was down-regulated significantly as
early as 6 hours into EGFR or ErbB2 inhibition on the protein
level as well that represents an immediate response (Fig. 4). These
results suggest that PHLDA1 is immediately and significantly
down-regulated by suppression of EGFR/ErbB2 signaling at both
mRNA and protein levels.
PHLDA1 is down-regulated in human breast cancers
We developed an IHC protocol for assessing expression of
PHLDA1 and performed IHC staining of whole tissue sections on
24 primary breast cancer cases including 12 ErbB2 positive and 12
ErbB2 negative breast adenocarcinomas tested by SISH study and
Figure 4. Downregulation of PHLDA1 expression upon ErbB2/EGFR inhibition. Western blot analysis following treatment with lapatinib,
erlotinib and CL387,785 at 1 mm for 6, 24 and 48 hours in ErbB2-positive SkBr3 and EGFR-mutated H1975, HCC827. DMSO treatment was 48 hours.
Different cell lines were used with the relevant inhibitor capable of blockade of oncogenic signaling.
doi:10.1371/journal.pone.0106349.g004
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Figure 5. PHLDA1 is down-regulated in human breast cancers. A. Immunohistochemical staining of PHLDA1 in 24 primary breast cancers. The
intensity of the staining of PHLDA1 was scored as 0 (no expression), 1+ (weak expression), 2+ (moderate expression) and 3+ (strong expression). SISH
was used to determine ErbB2 status in human breast cancer samples. B. Statistical analysis of IHC study. C, PHLDA1 is strongly expressed in normal
breast epithelium.
doi:10.1371/journal.pone.0106349.g005
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used available normal mammary tissues on the same slides as the
internal normal control. SISH was used to determine ErbB2 status
in human breast cancer samples. Scoring was performed by an
expert breast pathologist and an H-score was defined for all
samples (Fig. 5A). PHLDA1 expression was significantly reduced
in human breast cancer tissue versus adjacent normal mammary
epithelium (p,0.05) (Fig. 5B and 5C). The average score of
staining in tumor tissue was 2.09160.479 (mean6SD), while in
the normal control it was 2.38660.461 (mean6SD). Comparing
the ErbB2 positive with ErbB2 negative samples, PHLDA1 was
found to be significantly less expressed in ErbB2 negative tumor
slides (p,0.05). Of the 12 ErbB2 positive slides, the average score
of staining was 2.27360.41, while of the 12 ErbB2 negative slides,
the average score of staining was 1.87560.483 (Table 2). This
suggests robust expression of PHLDA1 in mammary epithelium,
downregulation of PHLDA1 in tumor versus adjacent normal
tissue suggestive of a putative tumor suppressor role and also
regulation by ErbB2 as suggested by the profiling studies as well.
We did not observe a significant correlation of PHLDA1
expression with ER status. We further determined the expression
of PHLDA1 by Western blotting in ErbB2 positive (HCC202 and
HCC1569) versus ErbB2 negative cell lines (MCF-7, T47D,
MDA-MB-436, MDA-MB-468 and HCC1937). All ErbB2-posi-
tive cell lines express PHLDA1 while expression is variable in
ErbB2-negative cell lines. In these cell lines PHLDA1 expression
might be regulated by multiple upstream pathways converging to
activate PHLDA1 expression besides ErbB2 (Figure S6).
PHLDA1 inhibits breast tumor cell proliferation and
migration
In order to further dissect the role of PHLDA1 in breast cancer
cells, PHLDA1 expression constructs were generated and expres-
sion of PHLDA1 was confirmed by detection of the hemagglutinin
tag (Fig. 6A). As early as 12 hours following transient transfection
of SkBr3 cells, PHLDA1 significantly inhibited phosphorylation of
AKT (Fig. 6B). Two PHLDA1 stable transfectants were selected in
SkBr3 cells as C2 and C4 clones and cell proliferation was
determined by MTS assay. PHLDA1 overexpression significantly
reduced cell growth at 96 hours compared with pcDNA3.1(-)-EV
stable transfectants in SkBr3 cells (Fig. 6C). The effect of PHLDA1
was further evaluated under anchorage-independent conditions.
The results showed that PHLDA1 overexpression resulted in a
dramatic loss in colony-forming ability (Fig. 6D). Thus, we showed
that PHLDA1 upregulation inhibits cell proliferation under
attached, as well as anchorage-independent conditions in breast
cancer cells. Next, cell motility was determined by wound-healing
assays in control and PHLDA1 overexpressing cells. PHLDA1
overexpression significantly decreased cell mobility, suggesting that
it negatively regulates chemotaxis (Fig. 6E). These results suggest a
strong growth-inhibitory effect of PHLDA1 in ErbB2-positive
cancer cells, likely via negative feedback regulation of AKT-driven
pathways.
PHLDA1 significantly enhances the sensitivity of ErbB2-
positive breast cancer cells to lapatinib
A clonogenic survival experiment was used to assess the role of
PHLDA1 in lapatinib sensitivity. The result of this experiment
showed that SkBr3 cells with forced overexpression of PHLDA1
were significantly more sensitive to lapatinib than cells transfected
with empty vector control. As shown in Figure 7, 0.1 mmol
lapatinib inhibits colony formation by 8% in empty vector
transfected cells while inhibits colony formation by 50% in
PHLDA1-transfected cells. These data indicate that PHLDA1
expression can increase lapatinib sensitivity in breast cancer cells.
Discussion
We set out to define novel ways to overcome resistance to
lapatinib and understand downstream pathways of oncogenic
ErbB2 signaling in ErbB2-dependent breast and non-small cell
lung cancer cells. We showed as expected that both lapatinib as
well as the irreversible ErbB2 inhibitor, PD168393 could induce
apoptosis and inhibit cell growth in ErbB2 positive lung and breast
cancer cell lines. This was correlated with a dose-dependent
reduction of phosphorylation of ErbB2 and its downstream
effectors, AKT and ERK1/2. In a random mutagenesis-based
resistance screen, a number of potential secondary ErbB2
mutations, including mutations of the gatekeeper T798 residue
were identified that might mediate acquired lapatinib-resistance.
T798I is analogous to the common gatekeeper mutations of EGFR
and BCR-ABL, EGFR-T790M and BCR-ABL T315I. We then
further showed the functional relevance of the T798I ErbB2
mutation as a potential resistance mechanism against reversible
ErbB2 inhibitors, modeled by lapatinib, in ErbB2-positive cancer
Table 2. Description of patient population of immunohistochemistry.










Age 49.5613.0 58.7621.3 NS
PHLDA1 expression 2.27360.41 1.87560.483 p,0.05
NS, not significant; IDC, invasive ductal carcinoma;
ILC, invasive lobular carcinoma.
doi:10.1371/journal.pone.0106349.t002
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cells. Indeed, T798I was confirmed to lead to functional resistance
to lapatinib with an about 3-fold increase in the IC50 of lapatinib.
As many imatinib-resistant mutations of BCR-ABL as well as the
recently identified D761Y mutation of EGFR lead to an IC50 shift
in this range, we predict that these mutations will be clinically
relevant. Our studies suggest that T798I-induced lapatinib
resistance can be overcome by irreversible dual ErbB2/EGFR
inhibitors, such as PD168393. Analogous irreversible inhibitors,
such as HKI-272 and BIBW2992, are being actively developed in
this setting. Preclinical results show that BIBW2992 is effective in
lung cancer models, including those with EGF receptor (EGFR)
mutations resistant to reversible first-generation EGFR inhibitors.
Epidermal growth factor receptor/ErbB2/vascular endothelial
growth factor receptor inhibitor EXEL-7647 was found to inhibit
almost all lapatinib resistance-associated mutations [16]. Rexer B
et al found that simultaneous blockade of HER2 and EGFR could
be an effective treatment strategy against HER2 gene-amplified
breast cancer cells harboring T798M mutant alleles [18]. Our
studies similarly suggest that irreversible ErbB2 inhibitors might be
able to overcome or prevent the development of potentially key
resistance mechanisms such as the gatekeeper secondary T798
mutation.
Next, we defined the comprehensive downstream changes upon
lapatinib treatment and only a very select number of genes were
altered as early as at 6 hours following ErbB2 blockade. This gene
list included a number of highly regulated genes shared by EGFR
blockade-induced changes in NSCLC as reported in our previous
study, such as cyclin D1, DUSPs, etc corroborating the accuracy
of our results and also demonstrating a very prominent overlap in
the regulated pathways [26,27]. We confirmed several of these
genes and many are indeed known to participate in key aspects of
oncogenic signaling modulation. E.g. cyclin D1 down-regulation
results in E2F deactivation with subsequent proliferation arrest
and ultimate apoptosis. DUSPs act as natural terminators of
MAPK signal transduction and serve as negative feedback
mechanisms. DUSP6 expression is regulated by ERK-signaling
and exerts anti-tumor effects via negative feedback regulation in
NSCLC [26].
Then, we focused on a strongly regulated novel gene, PHLDA1
as it has not been investigated before as a target of oncogenic
pathways. This gene shares a pleckstrin-homology (PH) domain
with PHLDA3, which was shown to be a direct target gene of p53
and functions as a unique AKT inhibitor through the depletion of
membrane-bound phosphatidyl inositols [29,30]. The exact
functions of PHLDA1 are poorly defined. Very little data exists
about the expression of PHLDA1 in normal or malignant human
tissues. In limited studies, PHLDA1 has been reported to be highly
expressed in pancreatic cancers as well as human intestinal tumors,
while downregulation of PHLDA1 was noted during melanoma as
well as breast cancer progression [31–35]. Johnson et al showed
that PHLDA1 correlates negatively with estrogen receptor
expression and is a strong inhibitor of cell motility, proliferation
and transformation in breast cancer cells [36]. PHLDA1 is
downregulated in primary breast tumors by immunohistochemis-
try [36]. However, in that study, there were only 2 ErbB2 positive
breast cancer samples, which did not permit strong conclusions. In
our study, we find that PHLDA1 is immediately and strongly
regulated by ErbB2 signaling. In addition, our in vivo study
showed a modest but significant down-regulation of PHLDA1 in
primary breast cancer, which is consistent with previously reported
findings [31,36]. We also found that PHLDA1 is significantly less
expressed in ErbB2 negative tumors compared with the ErbB2
positive breast cancers. In ErbB2 positive tumors, PHLDA1 protein
levels are higher than in ErbB2 negative ones which correlates well
with our finding of PHLDA1 expression being induced by ErbB2
signaling. We also demonstrated that PHLDA1 overexpression
could inhibit Akt activation, results in reduced cell proliferation and
cell motility consistent with its putative function as an Akt pathway
inhibitor and suggestive of a candidate tumor suppressor function.
These results provide evidence that reduced PHLDA1 expression
might be important in breast cancer progression as well as in the
modulation of oncogenic ErbB2 signaling and should call for more
detailed studies of PHLDA1 expression to assess if it could serve as a
useful prognostic marker of disease outcome and whether PHLDA1
expression might be lost in particular subsets of tumors. PHLDA1
overexpression significantly inhibits phosphorylation of AKT that
synergizes with lapatinib treatment in SkBr3 and such synergistic
effects on cell growth further corroborate a significant role for
PHLDA1 in the negative feedback regulation of ErbB2 activity.
Figure 6. Tumor suppressor activity of PHLDA1 in vitro. A. Western blotting of whole cell lysates with anti-PHLDA1 shows strong expression
of PHLDA1 in pcDNA3.1(-)-PHLDA1 transfected cells. B. Western blotting of cell lysates with pcDNA3.1(-)-PHLDA1 transient transfection shows potent
inhibition of AKT phosphorylation. C. MTS cell growth assay of pcDNA3.1(-)-EV and pcDNA3.1(-)-PHLDA1 stable clones. D. Soft Agar assay for
anchorage-independent cell growth is done with pcDNA3.1(-)-EV and pcDNA3.1(-)-PHLDA1 stable cell clones. E. Wound-healing assay shows that
PHLDA1 overexpression significantly decreased cell mobility. *: p,0.05.
doi:10.1371/journal.pone.0106349.g006
Figure 7. Clonogenic survival assay shows that PHLDA1
overexpression could significantly enhance lapatinib sensitiv-
ity in breast cancer cells. *: p,0.001; D: p,0.0001. Western blotting
of cell lysates with anti-HA shows equal exogenous expression of
PHLDA1 in pcDNA3.1(-)-PHLDA1 transfected cells after 10 days of
treatment with DMSO and 0.1 um lapatinib.
doi:10.1371/journal.pone.0106349.g007
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When the ErbB2 signaling is inhibited by lapatinib, phosphorylation
of AKT is downregulated. Consequently, PHLDA1 as the negative
feedback factor of ErbB2 pathway is downregulated by ErbB2
signaling inhibition. So PHLDA1 can fine-tune the overall output of
ErbB2 signaling in ErbB2 dependent lung and breast cancer cells.
We speculate that PHLDA1 might have key inhibitory functions in
EGFR and ErbB2-driven lung and breast cancer cells and a better
understanding of its functions might point at novel therapeutic
options through modulation of this important negative feedback
loop.
In summary, our studies define putative and novel resistance
mechanisms to lapatinib in ErbB2-positive cancers and identify
irreversible EGFR/ErbB2 inhibitors as capable of overcoming
such resistance. We also identify a compact set of gene changes
upon ErbB2 inhibition and demonstrate strong overlap with
EGFR-driven cancers and further identify PHLDA1 as a novel
negative feedback inhibitor and candidate tumor suppressor in
ErbB2-dependent cancers. Our studies in the aggregate should
yield multiple novel ways to expand the benefit of ErbB2 blockade
in ErbB2-dependent cancers.
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Figure S1 Lapatinib induces cell cycle arrest in SkBr3
cells as detected by BrdU assay. R1-G1 phase; R2-G2 phase;
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Figure S2 Dose response of lapatinib and PD168393 on
phosphorylation of ErbB2, AKT and ERK in Calu3 cells
stimulated with heregulin at 20 ng/ml.
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Figure S3 Dose-dependent growth inhibition induced by
lapatinib or PD168393 treatment for 72 hours in ErbB2-
wt and ErbB2-T798I transiently transfected SkBr3 cells
as detected by the MTS assay.
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Figure S4 Lapatinib and PD168393 induce cellular
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